Corcept Therapeutics (CORT) — FDA Issues CRL for Relacorilant Hypercortisolism NDA

What Happened

Event: On December 31, 2025, Corcept announced that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) for its relacorilant New Drug Application (NDA) for hypertension secondary to hypercortisolism; the application was not approved in this review cycle. (1)
CRL Details: Corcept said FDA acknowledged that GRACE met its primary endpoint and that GRADIENT provided confirmatory evidence, but could not reach a favorable benefit-risk assessment without additional evidence of effectiveness. The disclosed concern is the sufficiency of effectiveness evidence; the release does not define the work needed to address it. (1)

Trading Background

CORT was highly volatile but modestly lower overall, declining from $83.11 on September 30 to $79.82 on December 29, 2025. Shares fell 16.30% on October 10 after an October 9 Form 4 disclosed a pre-planned insider sale, later gained 7.81% on November 5 following Q3 results, and fell 7.08% on December 16 without a definitive company-specific catalyst identified. The 12.06% December 30 decline should be flagged separately: the FDA issued the CRL that day, but Corcept did not publicly announce it until December 31 at 8:00 a.m. EST, so the move should not be attributed to the CRL without evidence. (6) (5) (1)

Confirmed Information Based on Disclosures

Evidence relevant to the effectiveness concern: Corcept reported that FDA acknowledged GRACE met its primary endpoint and that GRADIENT provided confirmatory evidence. In its October 2024 report on GRADIENT in adrenal-origin Cushing syndrome, Corcept reported a statistically significant within-group systolic blood-pressure reduction, but the relacorilant-versus-placebo comparison was not statistically significant. (1) (2) (9)
Boundary of the affected application: The announcement separately identifies relacorilant’s platinum-resistant ovarian-cancer NDA and its July 11, 2026 PDUFA date; it reports no action on that application. (1) (7)
Existing-business baseline: Corcept reported company-wide revenue of about $207.6 million and operating cash flow of about $54.5 million for the quarter ended September 30, 2025. Its November 2025 company-wide revenue guidance was $800–$850 million, and the CRL announcement did not revise that guidance. (3) (4) (5)

Key Missing Information

The full FDA rationale and exact evidence requirement: The CRL and complete FDA rationale have not been publicly disclosed. (1)
The remediation and timing plan: Corcept has not disclosed a scheduled FDA meeting or a resubmission target, and the acceptable evidence path has not been stated. Accordingly, the exact work sequence and timing of the next regulatory decision cannot be pinned down. (1) (8)
Product-specific economics and full-path funding: No relacorilant hypercortisolism revenue forecast, company-specific remediation budget, or cash forecast through the next decision milestone is disclosed. (1) (3) (4)

Company's Response

Corcept said it plans to meet with FDA as soon as possible to discuss a path forward; it did not report a scheduled meeting or agreed remediation plan. CEO Joseph Belanoff expressed confidence that the company would find a way to reach patients, a management view rather than an established regulatory outcome. The release announced no completed remediation action or specific evidence-generation plan. (1)

News Release Framing Risks

The release says GRADIENT data “provided confirmatory evidence.” Paired with GRACE’s primary-endpoint result, that characterization may make the evidence appear uniformly strong, although the reported GRADIENT systolic-pressure comparison between relacorilant and placebo was not statistically significant. Because effectiveness evidence is the stated review barrier, the distinction matters; the release does not identify which evidence FDA considered insufficient or what would resolve the concern. (1) (2)

The CEO said, “I am confident we will find a way to get relacorilant to the patients it could help.” This confidence may suggest that eventual patient access is likely or that a workable path has been established, but it is a company opinion, not evidence of FDA agreement. The required evidence, regulatory route and timing remain unspecified. (1)

Analytical Interpretation

Pre-event expectation snapshot: Immediately before the event, FDA action was expected around the December 30, 2025 PDUFA target date, while U.S. commercialization remained dependent on regulatory approval and management’s expectation that regulatory deadlines would be met did not guarantee approval. (7) (5) (1)
Post-event change of expectation: The target-date action was a CRL, not approval, and potential U.S. commercialization is deferred pending additional effectiveness evidence, with the remediation path, timing and costs undetermined. (1)
Integrated assessment:
- The available record distinguishes evidence of activity from regulatory sufficiency: Corcept reports that GRACE met its primary endpoint, while the reported GRADIENT systolic-pressure comparison was not statistically significant between groups. This limits the strength of that confirmatory result but does not establish failure of the broader clinical thesis. (1) (2) (9)
- If review of the complete GRACE and GRADIENT data, valid analyses or available follow-up resolves the effectiveness inference and FDA accepts that approach, analysis and documentation could support resubmission without a new trial. (1) (8)
- If existing evidence cannot resolve the gap, a prospective controlled confirmatory efficacy study is a conditional alternative, not a disclosed FDA instruction. Its historical broad-scale cost is roughly $20–40 million per study—not a company budget or full-program cost—and depends on the eventual protocol. Continued operating costs and deferred commercial contribution could make the duration more consequential than the direct study expense. (1)
- The timing paths differ materially: the existing-data route could involve approximately 1–3 months of submission preparation and a conditional 9–18 months or longer from the CRL to a decision; the prospective-study route is multi-year, with a conditional 2028-or-later planning window. Any later FDA review follows resubmission and acceptance, and its classification and duration are not established. (8)
- FDA discussion and review of existing data can proceed in parallel. Feedback on whether that evidence can suffice or prospective confirmation is needed is the key branch selector and will narrow the expected timing path. (1) (8)
- The potential U.S. revenue and earnings contribution from the hypercortisolism indication is deferred, not established as permanently lost. Existing company-wide operations continue on the available evidence, so the principal financial effect is on the timing and certainty of prospective contribution. (1) (3)
- Recent sequential results show operating expenses growing approximately 17.7% against revenue growth of 6.8%, with operating margin at 4.9% in the quarter ended September 30, 2025, compared with 13.7% in the prior quarter. Delayed contribution while the operating base continues weakens the expected earnings-scaling trajectory, although two quarters do not establish a durable trend. (3) (4)
- Positive observed cash generation and substantial total liquidity support near-term absorption of bounded response work, but do not establish funding through a multi-year path. If prospective evidence is required, its duration could consume flexibility; no funding gap or actual diversion of other programs is established. (3) (4)
- The supported direct regulatory scope remains the hypercortisolism NDA. No direct propagation to the separate ovarian-cancer NDA or other programs is established; any broader capital-allocation effect depends on the remediation path and its duration. (1) (7)
- Overall implication of this event: The CRL primarily weakens Corcept’s expected growth, earnings and operating-leverage trajectory rather than its near-term viability: it defers potential contribution from the indication, while observed current revenue and cash generation support near-term work but do not establish coverage of a multi-year path. (1) (3) (4)